Share This Author
Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
- K. Ashida, Y. Sakurai, K. Iwakiri
- Medicine, BiologyAlimentary pharmacology & therapeutics
- 11 November 2015
TLDR
Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
- K. Ashida, Y. Sakurai, T. Chiba
- MedicineAlimentary pharmacology & therapeutics
- 22 July 2015
The potassium‐competitive acid blocker vonoprazan (VPZ) has potent acid‐inhibitory effects and may offer clinical advantages over conventional therapy for acid‐related disorders.
Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
- Y. Kinoshita, Y. Sakurai, K. Ashida
- MedicineCurrent therapeutic research, clinical and…
- 21 December 2016
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
- Y. Osuga, Yoshifumi Seki, Masataka Tanimoto, Takeru Kusumoto, K. Kudou, N. Terakawa
- MedicineFertility and sterility
- 7 September 2020
Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind…
- I. Tatsuno, Y. Saito, K. Kudou, Jun Ootake
- MedicineJournal of clinical lipidology
- 1 May 2013
A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis
- K. Iwakiri, Y. Sakurai, K. Ashida
- MedicineTherapeutic advances in gastroenterology
- 25 April 2017
TLDR
Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan
- Kazuhiro Suzuki, M. Namiki, Tsukasa Fujimoto, Nobuyoshi Takabayashi, K. Kudou, H. Akaza
- Medicine, BiologyJapanese journal of clinical oncology
- 20 October 2015
TLDR
Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
- M. Nishio, Tatsuya Yoshida, N. Yamamoto
- MedicineJournal of thoracic oncology : official…
- 25 November 2020
Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
- Y. Osuga, K. Enya, K. Kudou, Masataka Tanimoto, H. Hoshiai
- MedicineObstetrics and gynecology
- 1 March 2019
TLDR
Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.
- I. Tatsuno, Y. Saito, K. Kudou, Jun Ootake
- MedicineJournal of clinical lipidology
- 1 November 2013
...
...